NCT03450044: Immunogenicity and Safety of DCs in Breast Cancer

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: Female
Age: 30 Years to 65 Years (Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Metastasis to the central nervous system; Women over the age of 65 & under the age of 30

Comments are closed.

Up ↑